Resistance is Futile 1/21/2016. Disclosure Statement. History of Antimicrobial Development. Objectives. Bad Bugs, No Drugs
|
|
- Alfred Ford
- 5 years ago
- Views:
Transcription
1 Disclosure Statement Resistance is Futile Gerard L. Woolyhand, PharmD PGY 1 Resident St. Vincent s Medical Center Riverside NEFSHP Presentation January 23, 2016 I have nothing to disclose concerning possible financial or personal relationships with commercial entities that may have direct or indirect interest in the subject matter of this presentation. Objectives History of Antimicrobial Development Describe the Generating Antibiotic Incentives Now (GAIN) Act Identify new antimicrobial therapies approved by the Food and Drug Administration (FDA) Discuss the mechanism of action, side effects, and place in therapy of antimicrobials approved by the FDA Decrease in antimicrobial development : 6 antimicrobials Factors in development 1,2,3 Production cost Drug discovery shift Novel mechanism Controlling resistance 1. Spellberg B, et al. Clin Infect Dis. (2004) 38 (9): IDSA. Clin Infect Dis. (2011) 52 (suppl 5): S397 S ʺChallenges for the Development of New Antimicrobials Rethinking the Approaches: Report of a Workshop.ʺ Bad Bugs, No Drugs Bad bugs, no drugs report report 2 Target ESKAPE 10 x 20 Initiative 2 Initiated IDSA in 2010 Promotes research and development Revision to Food and Drug Administration Safety and Innovation Act of Generating Antibiotic Incentives Now (GAIN) Act Bill introduced in June 2011; passed in July Purpose to promote development of antibacterial and antifungal drugs 1,2,3 Response to increasing organism resistance Serious or life threatening infection 1. IDSA. Bad Bugs, No Drugs: As Antibiotic R&D Stagnates, a Public Health Crisis Brews. July Boucher HW, et al. Clin Infect Dis 2009;48: IDSA. Clin Infect Dis. (2010) 50 (8): ʺH.R.2182 Generating Antibiotic Incentives Now Act of FDA. The Federal Register. 79 FR Brown ED. Can J Microbiol Mar;59(3):
2 Defining Qualifying Pathogens Certain qualified pathogens FDA lists 4 criteria to be a qualified pathogen 1,2 Impact on public health Growth of drug resistant organisms Increase in resistance rates Morbidity and mortality Qualified pathogens Qualified Infectious Disease Product (QIDP) Generating Antibiotic Incentives Now (GAIN) Act Requires FDA to review clinical trial guidelines Recommendations by IDSA Consult with infectious disease and resistance experts Financial incentives Expedited review by FDA Market exclusivity for 5 additional years Additional 6 months for a companion diagnostic test 1. ʺH.R.2182 Generating Antibiotic Incentives Now Act of FDA. The Federal Register. 79 FR ʺH.R.2182 Generating Antibiotic Incentives Now Act of FDA. The Federal Register. 79 FR Antibiotic Timeline 2014 Dalbavancin (Dalvance ) Oritavancin (Orbactiv ) Ceftolozane Tazobactam Brand name: Zerbaxa Cephalosporin/ beta lactamase inhibitor combination Complex side chains overcome resistant mechanisms of P. aeruginosa Beta lactamase inhibitor prevents hydrolysis of ceftolozane Tedizolid (Sivextro ) Ceftolozane tazobactam (Zerbaxa ) 2015 Ceftazidime avibactam (Avycaz ) Isavuconazonium (Cresemba ) 1. Ceftolozane tazobactam (Zerbaxa) [package insert]. 2. Zhanel GG, et al. Drugs Jan;74(1): Ceftolozane Tazobactam MoA: Inhibits cell wall synthesis and binds to penicillin binding proteins (PBPs) 1 Bactericidal activity; time/mic parameter Indications 1,2 Complicated urinary tract infections (cuti) including pyelonephritis Complicated intra abdominal infections (ciai) with metronidazole Pending use for nosocomial pneumonia (phase III) Ceftolozane Tazobactam: Spectrum of Activity Gram negative Anaerobes Gram positive E. coli K. pneumoniae K. oxytoca P. aeruginosa P. mirabilis E. cloacae Prevotella Fusobacteriums Limited Clostridium species B. fragilis Streptococcus species Limited Staphylococcus species 1. Ceftolozane tazobactam (Zerbaxa) [package insert]. 2. Zhanel GG, et al. Drugs Jan;74(1): Ceftolozane Tazobactam (Zerbaxa) [package insert]. 2. Zhanel GG, et al. Drugs Jan;74(1): Snydman DR, et al. Antimicrob Agent Chemother. 2014;58(2):
3 Ceftolozane Tazobactam: Recommended Dosing 1 g ceftolozane/ 0.5 g tazobactam IV q8hr 1 Infusion time 1 hr 1 Pneumonia dose: 2 g ceftolozane/ 1 g tazobactam IV q8hr 1 Label confusion 2 Renal adjustment when creatinine clearance (CrCl) < 50 ml/min 3,4 Creatinine clearance* Recommendeddose 30 to 50 ml/min 500 mg/ 250 mg IV q8hr 15 to 29 ml/min 250 mg/ 125 mg IV q8hr < 15 ml/min No recommendation ESRD Single loading dose of 500 mg/ 250 mg IV; 100 mg/ 50 mg q8hr IV Ceftolozane Tazobactam Adverse effects 1,2 Nausea (5.2%) Diarrhea (3.9%) Headache (4.2%) Pyrexia (3.3%) Monitoring 2 Renal function Cost 3 Wholesale acquisition cost (WAC) $83 per vial WAC per day $25 $240 *Using Cockcroft Gault formula 1. Liscio JL, et al. Int J Antimicrob Agents Sep;46(3): ʺFDA Drug Safety Communication: Ceftolozane and Tazobactam). 3. ʺCeftolozane Tazobactam (Zerbaxa) [package insert]. 4. Zhanel GG, et al. Drugs Jan;74(1): Liscio JL, et al. Int J Antimicrob Agents Sep;46(3): Ceftolozane Tazobactam (Zerbaxa) [package insert]. 3. ʺProduct Guide for Pharmacy: Zerbaxa Ceftolozane Tazobactam.ʺ Ceftazidime Avibactam Brand name: Avycaz 3 rd generation cephalosporin/ beta lactamase inhibitor 1,2 MoA: Inhibits cell wall synthesis and binds to PBPs 1,3 Bactericidal activity; time/mic parameter Indications 1,2 cuti including pyelonephritis ciai Pending use nosocomial pneumonia (phase III) Avibactam: The New Kid on the Block Novel non beta lactam, beta lactamase inhibtor 1 Acyl enzyme stabilizes beta lactamase and promotes recyclization 2,3 Combined with beta lactam to extend spectrum of activity 1,4 Avibactam Clavulanic acid Tazobactam Sulbactam 1. Zhanel GG, et al. Drugs Feb;73(2): Lagacé Wiens P, et al. Core Evid Jan 24;9: Ceftazidime avibactam (Avycaz). [package insert] 1. Zhanel GG, et al. Drugs Feb;73(2): Winkler ML, et al. Antimicrob. Agents Chemother (7): Ehmann DE, et al. J Biol Chem (39): Lagacé Wiens P, et al. Core Evid Jan 24;9: Ceftazidime Avibactam: Spectrum of Activity Gram negative coverage 1 Avibactam enhances coverage to AmpC, CRE, and ESBL Ambler classification system 2 Classes A, C, and D 3 Klebsiella species E. coli MDR P. aeruginosa Citrobacter species Enterobacter species Ceftazidime Avibactam: Spectrum of Activity Gram positive Streptococcus species Limited Staphylococcus Ceftazidime avibactam not fully assessed Anaerobes B. fragilis C. perfringens Prevotella species 1. Lagacé Wiens P, et al. Core Evid Jan 24;9: Liscio JL, et al. Int J Antimicrob Agents Sep;46(3): Zhanel GG, et al. Drugs Feb;73(2): Lagacé Wiens P, et al. Core Evid Jan 24;9: Stachyra, et al. J Antimicrob Chemother. 2009;64: Zhanel GG, et al. Drugs Feb;73(2):
4 Ceftazidime Avibactam: Recommended Dosing 2 g ceftazidime/ 0.5 g IV avibactam Infusion time 2 hr Renal dose adjustment required Creatinine clearance* Recommended dose 31 to 50 ml/min 1 g/ 0.25 g IV q8hr 16 to 30 ml/min 0.75 g/ 0.19 g IV q12hr 6 to 15 ml/min 0.75 g/ 0.19 g IV q24hr Ceftazidime Avibactam Adverse effects( 10%) 1 Vomiting Nausea Constipation Anxiety Monitoring 1 Renal function Cost 2 WAC $285 per vial 5 ml/min 0.75 g/ 0.19 g IV q48hr *Using Cockcroft Gault formula Ceftazidime avibactam (Avycaz). [package insert]. 1. Ceftazidime avibactam (Avycaz). [package insert]. 2. ʺAvycaz Approval and Labeling Restrictions.ʺ Ceftolozane tazobactam Ceftazidime avibactam Novel structure Ceftolozane Avibactam Indications ciai and cuti ciai and cuti Pending pneumonia Pending pneumonia Microbiology Potent against P. aeruginosa Streptococcus species B. fragilis (CRE) Ambler classes A,C, D Streptococcus species B. fragilis C. perfringens Dosing q8hr, renal adjustment q8hr, renal adjustment Adverse events GI related GI related Clinical trials Phase III approval Phase II approval Limited evaluation of Cost $83 per vial $285 per vial Ceftazidime avibactam preferred therapy Liscio JL, et al. Int J Antimicrob Agents Sep;46(3): Tedizolid: The New Ox on the Block Brand name: Sivextro Oxazolidinone drug class 1 Prodrug tedizolid phosphate to tedizolid 1,2 MoA: Inhibits bacterial protein synthesis 1,2 Bacteriostatic activity; AUC/MIC parameter Overcomes chloramphenicol florfenicol resistance (cfr) resistance mechanism Indications 3 Acute bacterial skin and skin structure infections (ABSSSI) Pending approval for nosocomial pneumonia Dosing mg PO or IV q24hr for 6 days 1:1 conversion for IV to PO 1. Tedizolid (Sivextro) [package insert] 2. Wong E, et al. Pharmacy and Therapeutics. 2014;39(8): Zhanel GG, et al. Drugs Feb;75(3): Tedizolid: Spectrum of Activity Overcomes chloramphenicol florfenicol resistance (cfr) resistance mechanism Gram Positive 1,2 S. Aureus (MSSA and MRSA) Streptococcus species E.faecalis E. faecium Gram Negative 2 Anaerobes 3 Haemophilus influenzae Moraxella cattarhalis Bacteroides species Clostridum species Peptostreptococcus species Tedizolid Medication Safety Adverse effects 1,2 Nausea (8%) Headache (6%) Diarrhea (4%) Thrombocytopenia (2%) Incidence less in tedizolid 2.1% vs linezolid 4.5% (p=0.0175) Monitoring 1,3 CBC 1. Tedizolid (Sivextro) [package insert] 2. Kisgen JJ, et al. Am J Health Syst Pharm Apr 15;71(8): Zhanel GG, et al. Drugs Feb;75(3): Tedizolid (Sivextro) [package insert] 2. Zhanel GG, et al. Drugs Feb;75(3): Wong E, et al. Pharmacy and Therapeutics. 2014;39(8):
5 Tedizolid 1 Linezolid 2,3 Indications ABSSSI ABSSSI CAP and HCAP Microbiology Resistance MSSA MRSA Enterococcus species (VRE) Potent concentrations Overcome cfr resistance MSSA MRSA Enterococcus species (VRE) MRSA resistance Dosing 200 mg IV/PO for 6 days 600 mg IV/PO for 10 days Adverse events GI upset GI upset Thrombocytopenia (less) Thrombocytopenia Drug Interactions Cost Minimal MAO inhibitor No adrenergic agents No serotonergic agents $ per tablet $282 per vial MAO inhibitor Adrenergic agents Serotonergic agents $ per tablet $75 per IV solution 1. Tedizolid (Sivextro) [package insert] 2. Linezolid (Zyvox) [package insert]. Linezolid preferred therapy in clinical practice 3. Linezolid (Zyvox). Lexicomp Online. Isavuconazonium Sulfate Brand name: Cresemba Azole antifungal Prodrug that converts to active form isavuconazole 1 MoA: Inhibits the enzyme lanosterol 14 alphademethylase reducing production of ergosterol 1 Indications 1,2,3 Invasive aspergillosis Invasive mucormycosis 1. Isavuconazonium sulfate (Cresemba )[package insert]. 2. NCT Viljoen J, et al. Antimicrob Agents Chemother Mar;59(3): Isavuconazonium: Spectrum of Activity Mold and yeast 1 Aspergillus flavus Aspergillus fumigatus Aspergillus niger Mucorales (Rhizopus oryzae and mucormycetes species) Isavuconazonium: Dosage Forms and Dosing Capsule 186 mg 2 caps PO q8hr for 6 doses 186 mg 2 caps PO q24hr 186 mg of isavuconazonium sulfate is equivalent to 100 mg of isavuconazole Injection LD: 372 mg IV q8hr for 6 doses MD: 372 mg IV q24hr 372 mg of isavuconazonium sulfate is equivalent to 200 mg of isavuconazole 1. Isavuconazonium sulfate (Cresemba )[package insert] drug.htm Isavuconazonium sulfate (Cresemba )[package insert]. Isavuconazonium: Medication Safety Isavuconazonium Sulfate No renal impairment adjustments No mild or moderate hepatic adjustments; unknown with severe hepatic impairment Contraindications Strong CYP3A4 inhibitors/ inducers Short QT syndrome Warnings/ Precautions Hepatic adverse reactions Infusion related reactions Adverse effects ( 5%) 1 Nausea/ vomiting/ diarrhea Hypokalemia Cough Peripheral edema Back pain Monitoring 1 Liver function Infusion reactions Cost 2 AWP $84 per capsule AWP $ per vial Isavuconazonium sulfate (Cresemba )[package insert]. Isavuconazonium sulfate (Cresemba )[package insert]. Isavuconazonium (Cresemba). Lexicomp Online. 5
6 Isavuconazonium Sulfate Pros IV and PO options Daily dosing for maintenance Therapy for resistance or refractory patients Cons Limited clinical trials (small sample size) Drug interactions Place in therapy Second to third line option Summary GAIN Act promotes the creation of new antimicrobials that overcome MDRO Antimicrobials approved by the FDA provide clinical use in MDRO Recently approved antimicrobials have new mechanisms of actions, limited side effects, and distinct places in therapy Assessment Question #1 Which of the following drug class(es) does the GAIN Act provide incentives and promote as a QIDP? A. Antibacterials B. Antifungals C. Antivirals D. Anti parasitics E. A and B only Assessment Question #2 What feature describes ceftolozane tazobactam mechanism of action allowing it to overcome resistant mechanisms of P. aeruginosa? A. The beta lactamase inhibitor, tazobactam, is potent towards resistant mechanisms B. The complex side chains of ceftolozane are able to neutralize resistant mechanisms C. The large molecule size of ceftolozane diverts resistant mechanisms to tazobactam D. The potent killing activity of ceftolozane tazobactam overcomes resistant mechanisms Assessment Question #3 What feature(s) is/are TRUE about avibactam? A. Non beta lactam, beta lactamase inhibitor B. Recycling of the beta lactamase inhibitor allows repeated use to overcome resistance C. Avibactam enhances coverage to AmpC, CRE, and ESBL infections D. A and B only E. All statements above are true Resistance is Futile Gerard L. Woolyhand, PharmD PGY 1 Resident St. Vincent s Medical Center Riverside NEFSHP Presentation January 23,
7 Meet the Vancins Dalbavancin (Dalvance ) Indication: ABSSSI Dose: 1000 mg IV once; 500 mg IV 1 week later (over 30 min) Microbiology: S. aureus (including MRSA), Streptococcus species, and Enterococcus species Adverse effects: Nausea, headache, and diarrhea Oritavancin (Orbactiv ) Indication: ABSSSI Dose: 1200 mg IV single dose (infused 3 hr) Microbiology: S. aureus (including MRSA), Streptococcus species, and Enterococcus species Adverse effects: Nausea, vomiting, headache, and diarrhea Ceftazidime Avibactam: Spectrum of Activity Ambler Classification Enzyme Most Common Bacteria Class A Class B (metallo βlactamase) Class C KPC, SME, IMI, NMC, GES IMP, VIM, GIM, SPM AmpC, FOX, CMY, LAT, ACC, DHA (ESBL and carbapenemases) P. Aeruginosa Acinetobacter spp. Class D OXA Acinetobacter spp. Zhanel GG, et al. Drugs May 7;70(7): Lagacé Wiens P, et al. Core Evid Jan 24;9: Sader HS, et al. Antimicrob Agents Chemother. 2014;58(3): Zhanel GG, et al. Drugs Feb;73(2): Ceftolozane Tazobactam MIC Values Ceftazidime Avibactam MIC Values Ceftolozane tazobactam (Zerbaxa) [package insert]. Ceftazidime avibactam (Avycaz). [package insert] Tedizolid Phosphate MIC Values References 1. Spellberg B, Powers JH, Brass EP, et al. Trends in antimicrobial drug development: implications for the future. Clin Infect Dis. (2004) 38 (9): Infectious Diseases Society of America (IDSA). Combating antimicrobial resistance: policy recommendations to save lives. Clin Infect Dis. (2011) 52 (suppl 5): S397 S ʺChallenges for the Development of New Antimicrobials Rethinking the Approaches: Report of a Workshop.ʺ Treating Infectious Diseases in a Microbial World: Report of Two Workshops on Novel Antimicrobial Therapeutics. Washington, DC: The National Academies Press, IDSA. Bad Bugs, No Drugs: As Antibiotic R&D Stagnates, a Public Health Crisis Brews. July s/advancing_product_research_and_development/bad_bugs_no_drugs/statements/as%20an tibiotic%20discovery%20stagnates%20a%20public%20health%20crisis%20brews.pdf. Web. 10 Oct Boucher HW, Talbot GH, Bradley JS. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis. (2010) 50 (8): Infectious Diseases Society of America. The 10 ʹ20 Initiative: Pursuing a Global Commitment to Develop 10 New Antibacterial Drugs by Clin Infect Dis. (2010) 50 (8): Food and Drug Administration. Establishing a List of Qualifying Pathogens That Have the Potential to Pose a Serious Threat to Public Health Under the Food and Drug Administration Safety and Innovation Act. The Federal Register. 79 FR ʺH.R.2182 Generating Antibiotic Incentives Now Act of th Congress ( ).ʺ Library of Congress, 11 June Web. 29 Aug < bill/2182/text>. Tedizolid (Sivextro) [package insert] 7
8 References Continued 11. Brown ED, Is the GAIN Act a turning point in new antibiotic discovery? Can J Microbiol Mar;59(3): Liscio JL, Mahoney MV, Hirsch EB. Ceftolozane/tazobactam and ceftazidime/avibactam: two novel β lactam/β lactamase inhibitor combination agents for the treatment of resistant Gramnegative bacterial infections. Int J Antimicrob Agents Sep;46(3): ʺFDA Drug Safety Communication: FDA Cautions about Dose Confusion and Medication Errors for Antibacterial Drug Zerbaxa (ceftolozane and Tazobactam).ʺ U.S. Food and Drug Administration, 1 June Web. 26 Sept < 14. Ceftolozane Tazobactam (Zerbaxa) [package insert]. Lexington, MA: Cubist Pharmaceuticals; May Zhanel GG, Chung P, Adam H et al. Ceftolozane/tazobactam: a novel cephalosporin/βlactamase inhibitor combination with activity against multidrug resistant gram negative bacilli. Drugs Jan;74(1): Snydman DR, McDermott LA, Jacobus NV. Activity of ceftolozane tazobactam against a broad spectrum of recent clinical anaerobic isolates. Antimicrob Agents Chemother. 2014;58(2): ʺProduct Guide for Phamracy: Zerbaxa Ceftolozane Tazobactam.ʺ Merck Sharp & Dohme Corp, 1 June Web. 11 Oct < ordering dosing.pdf>. 18. Ceftazidime Avibactam (Avycaz). [package insert]. Verona, Italy: GlaxoSmithKline Manufacturing; February References Continued 19. Winkler ML, Papp Wallace KM, Taracila MA, et al. Avibactam and Inhibitor Resistant SHV {beta} Lactamases. Antimicrob. Agents Chemother (7): Ehmann DE, Jahic H, Ross PL, et al. Kinetics of Avibactam Inhibition against Class A, C, and D {beta} Lactamases. J Biol Chem (39): Sader HS, Castanheira M, Flamm RK et al. Antimicrobial activity of ceftazidime avibactam against Gram negative organisms collected from U.S. medical centers in Antimicrob Agents Chemother. 2014;58(3): Stachyra T, Premvathy L, Pechereau MC, et al. J Antimicrob Chemother. 2009;64: Zhanel GG, Lawson CD, Adam H, et al. Ceftazidime avibactam: a novel cephalosporin/βlactamase inhibitor combination. Drugs Feb;73(2): Lagacé Wiens P, Walkty A, and Karlowsky JA. eftazidime avibactam: an evidence based review of its pharmacology and potential use in the treatment of Gram negative bacterial infections. Core Evid Jan 24;9: ʺAvycaz Approval and Labeling Restrictions.ʺ Allphase Pharma Consulting LLC, 26 Aug Web. 12 Oct < approval and labelingrestrictions/>. 26. Tedizolid (Sivextro) [package insert]. Cubist Pharmaceuticals Inc.; Lexington (MA): July Wong E, Rab S. Tedizolid Phosphate (Sivextro): A Second Generation Oxazolidinone to Treat Acute Bacterial Skin and Skin Structure Infections.Pharmacy and Therapeutics. 2014;39(8): Zhanel GG, Love R, Adam H, et al. Tedizolid: a novel oxazolidinone with potent activity against multidrug. resistant gram positive pathogens. Drugs Feb;75(3): Kisgen JJ, Mansour H, Unger NR, et al. Tedizolid: a new oxazolidinone antimicrobial. Am J Health Syst Pharm Apr 15;71(8): References Continued 30. Linezolid (Zyvox) [package insert]. Pfizer US Pharmaceuticals; New York (NY): August Linezolid (Zyvox). Lexicomp Online, Pediatric and Neonatal Lexi Drugs Online, Hudson, Ohio: Lexi Comp, Inc.; Web. 15 Oct Isavuconazonium Sulfate (Cresemba )[package insert]. Northbrook, IL: Astellas Pharma US, Inc; April Isavuconazonium (Cresemba). Lexicomp Online, Pediatric and Neonatal Lexi Drugs Online, Hudson, Ohio: Lexi Comp, Inc.; Web. 14 Oct Zhanel GG, Calic D, Schweizer F, et al. New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin. Drugs May 7;70(7):
Samantha Trumm, Pharm.D. PGY-1 Resident Avera McKennan Hospital and University Center
Samantha Trumm, Pharm.D. PGY-1 Resident Avera McKennan Hospital and University Center I have had no financial relationship over the past 12 months with any commercial sponsor with a vested interest in
More informationAntimicrobials Update
Antimicrobials Update Rosie Amini, PharmD. BCPS Antimicrobial Stewardship Program Coordinator Swedish Medical Center Disclosures: Dr. Amini has no significant financial interest in any of the products
More informationThe role of new antibiotics in the treatment of severe infections: Safety and efficacy features
The role of new antibiotics in the treatment of severe infections Safety and efficacy features Christian Eckmann Hannover, Germany The role of new antibiotics in the treatment of severe infections: Safety
More informationNew Antibiotics for MRSA
New Antibiotics for MRSA Faculty Warren S. Joseph, DPM, FIDSA Consultant, Lower Extremity Infectious Diseases Roxborough Memorial Hospital Philadelphia, Pennsylvania Faculty Disclosure Dr. Joseph: Speaker
More informationWhat s next in the antibiotic pipeline?
What s next in the antibiotic pipeline? Jennifer Tieu, Pharm.D., BCPS Clinical Pearls OSHP Spring Meeting Mercy Hospital April 13, 2018 Objective 2 Describe the drug class and mechanism of action of antibiotics
More informationOther β-lactamase Inhibitor (BLI) Combinations: Focus on VNRX-5133, WCK 5222 and ETX2514SUL
Other β-lactamase Inhibitor (BLI) Combinations: Focus on VNRX-5133, WCK 5222 and ETX2514SUL David P. Nicolau, PharmD, FCCP, FIDSA Director, Center for Anti-Infective Research and Development Hartford Hospital
More informationIntrinsic, implied and default resistance
Appendix A Intrinsic, implied and default resistance Magiorakos et al. [1] and CLSI [2] are our primary sources of information on intrinsic resistance. Sanford et al. [3] and Gilbert et al. [4] have been
More informationNew Drugs for Bad Bugs- Statewide Antibiogram
New Drugs for Bad Bugs- Statewide Antibiogram Felicia Matthews, Pharm.D., BCPS Senior Consultant, Pharmacy Specialty BE MedMined Services Disclosures Employee of BD Corporation MedMined Services Agenda
More informationUpdates on the Management of Hospital Acquired Infections and Resistant Organisms
Updates on the Management of Hospital Acquired Infections and Resistant Organisms Conflict of Interest I, Kaitlin McGinn, have no actual or potential conflict of interest in relation to this program. Kaitlin
More informationUpdates on the Management of Hospital Acquired Infections and Resistant Organisms
Updates on the Management of Hospital Acquired Infections and Resistant Organisms Kaitlin McGinn, PharmD Assistant Clinical Professor, Critical Care Auburn University, Harrison School of Pharmacy November
More information4 th and 5 th generation cephalosporins. Naderi HR Associate professor of Infectious Diseases
4 th and 5 th generation cephalosporins Naderi HR Associate professor of Infectious Diseases Classification Forth generation: Cefclidine, cefepime (Maxipime),cefluprenam, cefoselis,cefozopran, cefpirome
More informationETX2514: Responding to the global threat of nosocomial multidrug and extremely drug resistant Gram-negative pathogens
ETX2514: Responding to the global threat of nosocomial multidrug and extremely drug resistant Gram-negative pathogens Ruben Tommasi, PhD Chief Scientific Officer ECCMID 2017 April 24, 2017 Vienna, Austria
More informationNew Antibiotics: Are They Really New?
New Antibiotics: Are They Really New? Donna E. Sweet, MD, MACP Professor of Medicine The University of Kansas School of Medicine - Wichita Antibiotics The First: Penicillin was discovered by Alexander
More informationAntibiotic Updates: Part I
Antibiotic Updates: Part I Fredrick M. Abrahamian, DO, FACEP, FIDSA Health Sciences Clinical Professor of Emergency Medicine David Geffen School of Medicine at UCLA Los Angeles, California Financial Disclosures
More informationMICRONAUT MICRONAUT-S Detection of Resistance Mechanisms. Innovation with Integrity BMD MIC
MICRONAUT Detection of Resistance Mechanisms Innovation with Integrity BMD MIC Automated and Customized Susceptibility Testing For detection of resistance mechanisms and specific resistances of clinical
More informationTreatment of Respiratory Tract Infections Prof. Mohammad Alhumayyd Dr. Aliah Alshanwani
Treatment of Respiratory Tract Infections Prof. Mohammad Alhumayyd Dr. Aliah Alshanwani 30-1-2018 1 Objectives of the lecture At the end of lecture, the students should be able to understand the following:
More informationAntimicrobial Stewardship:
Antimicrobial Stewardship: Inpatient and Outpatient Elements Angela Perhac, PharmD afperhac@carilionclinic.org Disclosure I have no relevant finances to disclose. Objectives Review the core elements of
More informationUSA Product Label CLINTABS TABLETS. Virbac. brand of clindamycin hydrochloride tablets. ANADA # , Approved by FDA DESCRIPTION
VIRBAC CORPORATION USA Product Label http://www.vetdepot.com P.O. BOX 162059, FORT WORTH, TX, 76161 Telephone: 817-831-5030 Order Desk: 800-338-3659 Fax: 817-831-8327 Website: www.virbacvet.com CLINTABS
More informationETX0282, a Novel Oral Agent Against Multidrug-Resistant Enterobacteriaceae
ETX0282, a Novel Oral Agent Against Multidrug-Resistant Enterobacteriaceae Thomas Durand-Réville 02 June 2017 - ASM Microbe 2017 (Session #113) Disclosures Thomas Durand-Réville: Full-time Employee; Self;
More informationAntibiotic. Antibiotic Classes, Spectrum of Activity & Antibiotic Reporting
Antibiotic Antibiotic Classes, Spectrum of Activity & Antibiotic Reporting Any substance of natural, synthetic or semisynthetic origin which at low concentrations kills or inhibits the growth of bacteria
More informationOther Beta - lactam Antibiotics
Other Beta - lactam Antibiotics Assistant Professor Dr. Naza M. Ali Lec 5 8 Nov 2017 Lecture outlines Other beta lactam antibiotics Other inhibitors of cell wall synthesis Other beta-lactam Antibiotics
More informationBurton's Microbiology for the Health Sciences. Chapter 9. Controlling Microbial Growth in Vivo Using Antimicrobial Agents
Burton's Microbiology for the Health Sciences Chapter 9. Controlling Microbial Growth in Vivo Using Antimicrobial Agents Chapter 9 Outline Introduction Characteristics of an Ideal Antimicrobial Agent How
More informationChildrens Hospital Antibiogram for 2012 (Based on data from 2011)
Childrens Hospital Antibiogram for 2012 (Based on data from 2011) Prepared by: Department of Clinical Microbiology, Health Sciences Centre For further information contact: Andrew Walkty, MD, FRCPC Medical
More informationAntimicrobial stewardship: Quick, don t just do something! Stand there!
Antimicrobial stewardship: Quick, don t just do something! Stand there! Stanley I. Martin, MD, FACP, FIDSA Director, Division of Infectious Diseases Director, Antimicrobial Stewardship Program Geisinger
More informationNorthwestern Medicine Central DuPage Hospital Antimicrobial Criteria Updated 11/16/16
Northwestern Medicine Central DuPage Hospital Antimicrobial Criteria Updated 11/16/16 These criteria are based on national and local susceptibility data as well as Infectious Disease Society of America
More information220/146 mmhg. Disclosures. New Antibiotics for the Post-Antibiotic Era. Objectives for Technicians. Objectives for Pharmacists 8/30/2016
Disclosures New Antibiotics for the Post-Antibiotic Era I have no conflicts of interest relative to the content of this presentation Eric Wenzler, PharmD, BCPS Infectious Diseases Pharmacotherapy Fellow
More informationAntimicrobial Cycling. Donald E Low University of Toronto
Antimicrobial Cycling Donald E Low University of Toronto Bad Bugs, No Drugs 1 The Antimicrobial Availability Task Force of the IDSA 1 identified as particularly problematic pathogens A. baumannii and
More informationAntibiotic Updates: Part II
Antibiotic Updates: Part II Fredrick M. Abrahamian, DO, FACEP, FIDSA Health Sciences Clinical Professor of Emergency Medicine David Geffen School of Medicine at UCLA Los Angeles, California Financial Disclosures
More informationOPTIMIZATION OF PK/PD OF ANTIBIOTICS FOR RESISTANT GRAM-NEGATIVE ORGANISMS
HTIDE CONFERENCE 2018 OPTIMIZATION OF PK/PD OF ANTIBIOTICS FOR RESISTANT GRAM-NEGATIVE ORGANISMS FEDERICO PEA INSTITUTE OF CLINICAL PHARMACOLOGY DEPARTMENT OF MEDICINE, UNIVERSITY OF UDINE, ITALY SANTA
More informationAntimicrobials. Antimicrobials
Antimicrobials For more than 50 years, antibiotics have come to the rescue by routinely producing rapid and long-lasting miracle cures. However, from the beginning antibiotics have selected for resistance
More informationRise of Resistance: From MRSA to CRE
Rise of Resistance: From MRSA to CRE Paul D. Holtom, MD Professor of Medicine and Orthopaedics USC Keck School of Medicine SUPERBUGS (AKA MDROs) MRSA Methicillin-resistant S. aureus Evolution of Drug Resistance
More informationAntibiotics 201 for Laboratory Professionals
Antibiotics 201 for Laboratory Professionals Erik Munson, Ph.D., D(ABMM) Marquette University Wisconsin Clinical Laboratory Network Technical Advisory Group The presenter states no conflict of interest
More informationWitchcraft for Gram negatives
Witchcraft for Gram negatives Dr Subramanian S MD DNB MNAMS AB (Medicine, Infect Dis) Infectious Diseases Consultant Global Health City, Chennai www.asksubra.com Drug resistance follows the drug like a
More informationAntibiotics 201 for Laboratory Professionals
Antibiotics 201 for Laboratory Professionals Erik Munson, Ph.D., D(ABMM) Marquette University Wisconsin Clinical Laboratory Network Technical Advisory Group The presenter states no conflict of interest
More informationMercy Medical Center Des Moines, Iowa Department of Pathology. Microbiology Department Antibiotic Susceptibility January December 2016
Mercy Medical Center Des Moines, Iowa Department of Pathology Microbiology Department Antibiotic Susceptibility January December 2016 These statistics are intended solely as a GUIDE to choosing appropriate
More informationComparative Assessment of b-lactamases Produced by Multidrug Resistant Bacteria
Comparative Assessment of b-lactamases Produced by Multidrug Resistant Bacteria Juhee Ahn Department of Medical Biomaterials Engineering Kangwon National University October 23, 27 Antibiotic Development
More informationClinical Policy: Linezolid (Zyvox) Reference Number: CP.PMN.27 Effective Date: Last Review Date: Line of Business: HIM*, Medicaid
Clinical Policy: (Zyvox) Reference Number: CP.PMN.27 Effective Date: 09.01.06 Last Review Date: 02.19 Line of Business: HIM*, Medicaid Coding Implications Revision Log See Important Reminder at the end
More informationThe β- Lactam Antibiotics. Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan November 2018
The β- Lactam Antibiotics Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan November 2018 Penicillins. Cephalosporins. Carbapenems. Monobactams. The β- Lactam Antibiotics 2 3 How
More informationScottish Medicines Consortium
Scottish Medicines Consortium tigecycline 50mg vial of powder for intravenous infusion (Tygacil ) (277/06) Wyeth 9 June 2006 The Scottish Medicines Consortium (SMC) has completed its assessment of the
More information4/3/2017 CLINICAL PEARLS: UPDATES IN THE MANAGEMENT OF NOSOCOMIAL PNEUMONIA DISCLOSURE LEARNING OBJECTIVES
CLINICAL PEARLS: UPDATES IN THE MANAGEMENT OF NOSOCOMIAL PNEUMONIA BILLIE BARTEL, PHARMD, BCCCP APRIL 7 TH, 2017 DISCLOSURE I have had no financial relationship over the past 12 months with any commercial
More informationAntibiotic Resistance. Antibiotic Resistance: A Growing Concern. Antibiotic resistance is not new 3/21/2011
Antibiotic Resistance Antibiotic Resistance: A Growing Concern Judy Ptak RN MSN Infection Prevention Practitioner Dartmouth-Hitchcock Medical Center Lebanon, NH Occurs when a microorganism fails to respond
More informationAppropriate Antimicrobial Therapy for Treatment of
Appropriate Antimicrobial Therapy for Treatment of Staphylococcus aureus infections ( MRSA ) By : A. Bojdi MD Assistant Professor Inf. Dis. Dep. Imam Reza Hosp. MUMS Antibiotics Still Miracle Drugs Paul
More informationCefazolin vs. Antistaphyloccal Penicillins: The Great Debate
Cefazolin vs. Antistaphyloccal Penicillins: The Great Debate Annie Heble, PharmD PGY2 Pediatric Pharmacy Resident Children s Hospital Colorado Microbiology Rounds March 22, 2017 Image Source: Buck cartoons
More informationPharmacology Week 6 ANTIMICROBIAL AGENTS
Pharmacology Week 6 ANTIMICROBIAL AGENTS Mechanisms of antimicrobial action Mechanisms of antimicrobial action Bacteriostatic - Slow or stop bacterial growth, needs an immune system to finish off the microbe
More informationFlorida Health Care Association District 2 January 13, 2015 A.C. Burke, MA, CIC
Florida Health Care Association District 2 January 13, 2015 A.C. Burke, MA, CIC 11/20/2014 1 To describe carbapenem-resistant Enterobacteriaceae. To identify laboratory detection standards for carbapenem-resistant
More informationMechanism of antibiotic resistance
Mechanism of antibiotic resistance Dr.Siriwoot Sookkhee Ph.D (Biopharmaceutics) Department of Microbiology Faculty of Medicine, Chiang Mai University Antibiotic resistance Cross-resistance : resistance
More informationCONTAGIOUS COMMENTS Department of Epidemiology
VOLUME XXIII NUMBER 1 July 2008 CONTAGIOUS COMMENTS Department of Epidemiology Bugs and Drugs Elaine Dowell, SM (ASCP), Marti Roe SM (ASCP), Ann-Christine Nyquist MD, MSPH Are the bugs winning? The 2007
More informationCritical impact of antimicrobial resistance
New Antibiotics Kurt B. Stevenson, MD, MPH Professor of Medicine and Epidemiology Division of Infectious Diseases Department of Internal Medicine The Ohio State University College of Medicine Critical
More informationBad Bugs. Pharmacist Learning Objectives. Antimicrobial Resistance. Patient Case. Pharmacy Technician Learning Objectives 4/8/2016
Pharmacist Learning Objectives Antimicrobial Resistance Julie Giddens Pharm D, BCPS Infectious Disease Clinical Pharmacist OSF Saint Francis Medical Center Peoria, IL The speaker has no conflicts to disclose
More informationAntimicrobial Therapy
Antimicrobial Therapy David H. Spach, MD Professor of Medicine Division of Infectious Diseases University of Washington, Seattle Disclosure: Dr. Spach has no significant financial interest in any of the
More informationLe infezioni di cute e tessuti molli
Le infezioni di cute e tessuti molli SCELTE e STRATEGIE TERAPEUTICHE Pierluigi Viale Clinica di Malattie Infettive Policlinico S. Orsola Malpighi Treatment of complicated skin and skin structure infections
More informationBreaking the Ring. β-lactamases and the Great Arms Race. Bryce M Kayhart, PharmD, BCPS PGY2 Pharmacotherapy Resident Mayo Clinic - Rochester
Breaking the Ring β-lactamases and the Great Arms Race Bryce M Kayhart, PharmD, BCPS PGY2 Pharmacotherapy Resident Mayo Clinic - Rochester 2015 MFMER slide-1 Disclosures I have no relevant financial relationships
More informationRESISTANT PATHOGENS. John E. Mazuski, MD, PhD Professor of Surgery
RESISTANT PATHOGENS John E. Mazuski, MD, PhD Professor of Surgery Disclosures Contracted Research: AstraZeneca, Bayer, Merck. Advisory Boards/Consultant: Allergan (Actavis, Forest Laboratories), AstraZeneca,
More informationAppropriate antimicrobial therapy in HAP: What does this mean?
Appropriate antimicrobial therapy in HAP: What does this mean? Jaehee Lee, M.D. Kyungpook National University Hospital, Korea KNUH since 1907 Presentation outline Empiric antimicrobial choice: right spectrum,
More informationPRACTIC GUIDELINES for APPROPRIATE ANTIBIOTICS USE
PRACTIC GUIDELINES for APPROPRIATE ANTIBIOTICS USE Global Alliance for Infection in Surgery World Society of Emergency Surgery (WSES) and not only!! Aims - 1 Rationalize the risk of antibiotics overuse
More information2012 ANTIBIOGRAM. Central Zone Former DTHR Sites. Department of Pathology and Laboratory Medicine
2012 ANTIBIOGRAM Central Zone Former DTHR Sites Department of Pathology and Laboratory Medicine Medically Relevant Pathogens Based on Gram Morphology Gram-negative Bacilli Lactose Fermenters Non-lactose
More informationBACTERIAL SUSCEPTIBILITY REPORT: 2016 (January 2016 December 2016)
BACTERIAL SUSCEPTIBILITY REPORT: 2016 (January 2016 December 2016) VA Palo Alto Health Care System April 14, 2017 Trisha Nakasone, PharmD, Pharmacy Service Russell Ryono, PharmD, Public Health Surveillance
More informationGORILLACILLINS IN THE ICU:
Conflicts of Interest None to declare GORILLACILLINS IN THE ICU: From SPACE and Beyond... Tim T.Y. Lau, PharmD, FCSHP Clinical Pharmacy Specialist in Infectious Diseases Pharmaceutical Sciences, Vancouver
More information2015 Antibiogram. Red Deer Regional Hospital. Central Zone. Alberta Health Services
2015 Antibiogram Red Deer Regional Hospital Central Zone Alberta Health Services Introduction. This antibiogram is a cumulative report of the antimicrobial susceptibility rates of common microbial pathogens
More informationETX2514SUL (sulbactam/etx2514) for the treatment of Acinetobacter baumannii infections
ETX2514SUL (sulbactam/etx2514) for the treatment of Acinetobacter baumannii infections Robin Isaacs Chief Medical Officer, Entasis Therapeutics Dr. Isaacs is a full-time employee of Entasis Therapeutics.
More informationAmoxicillin Introduction: Mechanism of action: Pharmacology: Indications: Dosage: 12 Weeks ( 3 Months):
Amoxicillin Introduction: A semisynthetic antibiotic, an analog of ampicillin, with a broad spectrum of bactericidal activity against many gram-positive and gram-negative microganisms. Mechanism of action:
More informationDisclosures. Principles of Antimicrobial Therapy. Obtaining an Accurate Diagnosis Obtain specimens PRIOR to initiating antimicrobials
Disclosures Principles of Antimicrobial Therapy None Lori A. Cox MSN, ACNP-BC, ACNPC, FCCM Penn State Hershey Medical Center Neuroscience Critical Care Unit Obtaining an Accurate Diagnosis Determine site
More informationClinical Policy: Linezolid (Zyvox) Reference Number: CP.PMN.27 Effective Date: Last Review Date: Line of Business: Oregon Health Plan
Clinical Policy: (Zyvox) Reference Number: CP.PMN.27 Effective Date: 07.01.18 Last Review Date: 05.18 Line of Business: Oregon Health Plan Revision Log See Important Reminder at the end of this policy
More information* gender factor (male=1, female=0.85)
Usual Doses of Antimicrobials Typically Not Requiring Renal Adjustment Azithromycin 250 500 mg Q24 *Amphotericin B 1 3-5 mg/kg Q24 Clindamycin 600 900 mg Q8 Liposomal (Ambisome ) Doxycycline 100 mg Q12
More informationAddressing the evolving challenge of β-lactamase mediated antimicrobial resistance: ETX2514, a next-generation BLI with potent broadspectrum
Addressing the evolving challenge of β-lactamase mediated antimicrobial resistance: ETX2514, a next-generation BLI with potent broadspectrum activity against Class A, C and D enzymes Alita Miller, PhD
More informationANTIBIOTICS: TECHNOLOGIES AND GLOBAL MARKETS
ANTIBIOTICS: TECHNOLOGIES AND GLOBAL MARKETS PHM025D March 2016 Neha Maliwal Project Analyst ISBN: 1-62296-252-4 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215 (toll-free
More informationChallenges Emerging resistance Fewer new drugs MRSA and other resistant pathogens are major problems
Micro 301 Antimicrobial Drugs 11/7/12 Significance of antimicrobial drugs Challenges Emerging resistance Fewer new drugs MRSA and other resistant pathogens are major problems Definitions Antibiotic Selective
More informationPfizer Position on Antimicrobial Resistance Management. Kirill Tverskoy, Medical Director Pfizer Russia February 21, 2017
Pfizer Position on Antimicrobial Resistance Management Kirill Tverskoy, Medical Director Pfizer Russia February 21, 2017 Objectives and Trends of Nowadays Healthcare Environment Effective and innovative
More informationSuper Bugs and Wonder Drugs: Protecting the One While Respecting the Many
Super Bugs and Wonder Drugs: Protecting the One While Respecting the Many Vicki Stringfellow, MSN, CPNP-AC/PC Werner Division of Pediatric Critical Care University of Kentucky Lexington, KY Disclosure
More informationSafe Patient Care Keeping our Residents Safe Use Standard Precautions for ALL Residents at ALL times
Safe Patient Care Keeping our Residents Safe 2016 Use Standard Precautions for ALL Residents at ALL times #safepatientcare Do bugs need drugs? Dr Deirdre O Brien Consultant Microbiologist Mercy University
More informationDoripenem: A new carbapenem antibiotic a review of comparative antimicrobial and bactericidal activities
REVIEW Doripenem: A new carbapenem antibiotic a review of comparative antimicrobial and bactericidal activities Fiona Walsh Department of Clinical Microbiology, Trinity College Dublin, Dublin, Ireland
More informationAntibacterials. Recent data on linezolid and daptomycin
Antibacterials Recent data on linezolid and daptomycin Patricia Muñoz, MD. Ph.D. (pmunoz@micro.hggm.es) Hospital General Universitario Gregorio Marañón Universidad Complutense de Madrid. 1 GESITRA Reasons
More informationNew Antibiotics & New Insights into Old Antibiotics
New Antibiotics & New Insights into Old Antibiotics Louisiana Chapter of the American Academy of Pediatrics August 18, 2018 Baton Rouge, Louisiana John Bradley MD Rady Children s Hospital San Diego University
More informationCombating Drug-Resistant Infections Globally. Company Presentation
Combating Drug-Resistant Infections Globally Company Presentation Forward-Looking Statements and Other Important Cautions Any statement in this presentation about our future expectations, plans and prospects,
More informationANTIBIOTICS USED FOR RESISTACE BACTERIA. 1. Vancomicin
ANTIBIOTICS USED FOR RESISTACE BACTERIA 1. Vancomicin Vancomycin is used to treat infections caused by bacteria. It belongs to the family of medicines called antibiotics. Vancomycin works by killing bacteria
More informationMedicinal Chemistry 561P. 2 st hour Examination. May 6, 2013 NAME: KEY. Good Luck!
Medicinal Chemistry 561P 2 st hour Examination May 6, 2013 NAME: KEY Good Luck! 2 MDCH 561P Exam 2 May 6, 2013 Name: KEY Grade: Fill in your scantron with the best choice for the questions below: 1. Which
More informationSkin and Soft Tissue Infections Emerging Therapies and 5 things to know
2011 MFMER slide-1 Skin and Soft Tissue Infections Emerging Therapies and 5 things to know Aaron Tande, MD Assistant Professor of Medicine October 27, 2017 Division of INFECTIOUS DISEASES 2011 MFMER slide-2
More informationEARS Net Report, Quarter
EARS Net Report, Quarter 4 213 March 214 Key Points for 213* Escherichia coli: The proportion of patients with invasive infections caused by E. coli producing extended spectrum β lactamases (ESBLs) increased
More informationGeneral Infectious Disease Concepts/Resources
General Infectious Disease Concepts/Resources Learning Objectives: 1. Distinguish between foundational infectious disease concepts including gram positive and negative bacteria, bacteriostatic and bactericidal
More informationMulti-drug resistant microorganisms
Multi-drug resistant microorganisms Arzu TOPELI Director of MICU Hacettepe University Faculty of Medicine, Ankara-Turkey Council Member of WFSICCM Deaths in the US declined by 220 per 100,000 with the
More informationRecommendations for Implementation of Antimicrobial Stewardship Restrictive Interventions in Acute Hospitals in Ireland
Recommendations for Implementation of Antimicrobial Stewardship Restrictive Interventions in Acute Hospitals in Ireland A report by the Hospital Antimicrobial Stewardship Working Group, a subgroup of the
More informationß-lactams. Sub-families. Penicillins. Cephalosporins. Monobactams. Carbapenems
β-lactams ß-lactams Sub-families Penicillins Cephalosporins Monobactams Carbapenems ß-lactams Mode of action PBPs = Trans/Carboxy/Endo- peptidases PBP binding (Penicillin-Binding Proteins) activation of
More informationAntibiotic Update. Disclosure. Technician Objectives. Pharmacist Objectives. Antibiotic Resistance. Antibiotic Resistance Threats 3/5/2015
Antibiotic Update Ashley Gustafson, Pharm.D., BCPS PGY-2 Critical Care Pharmacy Resident Baptist Hospital of Miami Disclosure I do not have a vested interest in or affiliation with any corporate organization
More informationLefamulin Evaluation Against Pneumonia (LEAP 1) Phase 3 Topline Results. September 18, 2017
Lefamulin Evaluation Against Pneumonia (LEAP 1) Phase 3 Topline Results September 18, 2017 Safe Harbor and Disclaimer Any statements in this presentation about future expectations, plans and prospects
More informationAntimicrobial Pharmacodynamics
Antimicrobial Pharmacodynamics November 28, 2007 George P. Allen, Pharm.D. Assistant Professor, Pharmacy Practice OSU College of Pharmacy at OHSU Objectives Become familiar with PD parameters what they
More informationZyvox. Zyvox (linezolid) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.20 Subject: Zyvox Page: 1 of 7 Last Review Date: March 18, 2016 Zyvox Description Zyvox (linezolid)
More informationAntibiotics and Stewardship: What s New in Pediatrics-Land?
Antibiotics and Stewardship: What s New in Pediatrics-Land? Sean P. Elliott, MD Professor of Pediatrics Associate Chair of Education, Department of Pediatrics University of Arizona College of Medicine
More informationFundamental Concepts in the Use of Antibiotics. Case. Case. TM is a 24 year old male admitted to ICU after TBI and leg fracture from MVA ICU day 3
Fundamental Concepts in the Use of Antibiotics Todd Miano, PharmD, MSCE Critical Care Pharmacist Pharmacoepidemiology Fellow Perelman School of Medicine at the University of Pennsylvania Case TM is a 24
More informationNew Opportunities for Microbiology Labs to Add Value to Antimicrobial Stewardship Programs
New Opportunities for Microbiology Labs to Add Value to Antimicrobial Stewardship Programs Patrick R. Murray, PhD Senior Director, WW Scientific Affairs 2017 BD. BD, the BD Logo and all other trademarks
More informationFighting MDR Pathogens in the ICU
Fighting MDR Pathogens in the ICU Dr. Murat Akova Hacettepe University School of Medicine, Department of Infectious Diseases, Ankara, Turkey 1 50.000 deaths each year in US and Europe due to antimicrobial
More informationSIVEXTRO (tedizolid phosphate) oral tablet ZYVOX (linezolid) oral suspension and tablet
ZYVOX (linezolid) oral suspension and tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This
More information1/30/ Division of Disease Control and Health Protection. Division of Disease Control and Health Protection
Surveillance, Outbreaks, and Reportable Diseases, Oh My! Assisted Living Facility, Nursing Home and Surveyor Infection Prevention Training February 2015 A.C. Burke, MA, CIC Health Care-Associated Infection
More informationGUIDELINES FOR THE MANAGEMENT OF COMMUNITY-ACQUIRED PNEUMONIA IN ADULTS
Version 3.1 GUIDELINES FOR THE MANAGEMENT OF COMMUNITY-ACQUIRED PNEUMONIA IN ADULTS Date ratified June 2008 Updated March 2009 Review date June 2010 Ratified by Authors Consultation Evidence base Changes
More informationInfection Control of Emerging Diseases
2016 EPS Training Event Martin E. Evans, MD Director, VHA MDRO Program National Infectious Diseases Service Lexington, KY & Cincinnati, OH Infection Control of Emerging Diseases 2016 EPS Training Event
More informationInhibiting Microbial Growth in vivo. CLS 212: Medical Microbiology Zeina Alkudmani
Inhibiting Microbial Growth in vivo CLS 212: Medical Microbiology Zeina Alkudmani Chemotherapy Definitions The use of any chemical (drug) to treat any disease or condition. Chemotherapeutic Agent Any drug
More informationSESSION XVI NEW ANTIBIOTICS
SESSION XVI NEW ANTIBIOTICS New Antibiotics to Treat Anaerobic Infections 2 Goldstein, E.J.C.;* Citron, D.M. Antibiotic Pharmacodynamics 3 Stein, G.E.* Targeting Selenium Metabolism in Stickland Fermentors:
More information2017 Antibiogram. Central Zone. Alberta Health Services. including. Red Deer Regional Hospital. St. Mary s Hospital, Camrose
2017 Antibiogram Central Zone Alberta Health Services including Red Deer Regional Hospital St. Mary s Hospital, Camrose Introduction This antibiogram is a cumulative report of the antimicrobial susceptibility
More informationRise of the Superbugs: the end of antibiotics? Peter Lambert Life and Health Sciences Aston University
Rise of the Superbugs: the end of antibiotics? Peter Lambert Life and Health Sciences Aston University Willard Wigan Microbiologists grow bacteria on plates Each colony is formed from a single cell Colonies
More informationTable 1. Commonly encountered or important organisms and their usual antimicrobial susceptibilities.
Table 1. Commonly encountered or important organisms and their usual antimicrobial susceptibilities. Gram-positive cocci: Staphylococcus aureus: *Resistance to penicillin is almost universal. Resistance
More information2016 Antibiogram. Central Zone. Alberta Health Services. including. Red Deer Regional Hospital. St. Mary s Hospital, Camrose
2016 Antibiogram Central Zone Alberta Health Services including Red Deer Regional Hospital St. Mary s Hospital, Camrose Introduction This antibiogram is a cumulative report of the antimicrobial susceptibility
More information